Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xeloda capecitabine: Additional Phase III data

Additional data from the open-label, international Phase III X-ACT trial in 1,987

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE